Biolyst › KYTXKyverna Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on October 23, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 14.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Track KYTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open KYTX in the tracker
Recent history
Date Event Type Phase
September 24, 2026
8-K filed: Reg FD disclosure Filing
—
August 11, 2026
Quarterly results filed (8-K) Earnings
—
July 27, 2026
8-K filed: Material agreement, Reg FD disclosure Corporate
—
July 9, 2026
8-K filed: Material agreement Corporate
—
June 25, 2026
KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome Trial Milestone
Phase 2
June 16, 2026
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis Trial Milestone
Phase 1/Phase 2
May 29, 2026
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis Trial Milestone
Phase 1/Phase 2
May 18, 2026
8-K filed: Leadership change, Other event Corporate
—
May 12, 2026
Quarterly results filed (8-K) Earnings
—
May 4, 2026
8-K filed: Other event Filing
—
April 22, 2026
8-K filed: Reg FD disclosure Filing
—
April 22, 2026
8-K filed: Reg FD disclosure Filing
—
April 20, 2026
8-K filed: Reg FD disclosure Filing
—
March 26, 2026
Quarterly results filed (8-K) Earnings
—
February 24, 2026
8-K filed: Leadership change, Other event Corporate
—
February 3, 2026
8-K filed: Leadership change, Other event Corporate
—
January 12, 2026
Quarterly results filed (8-K) Earnings
—
December 22, 2025
KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis Trial Milestone
Phase 1/Phase 2
December 18, 2025
8-K filed: Material agreement, Other event Corporate
—
December 15, 2025
8-K filed: Reg FD disclosure Filing
—
December 15, 2025
8-K filed: Reg FD disclosure Filing
—
November 12, 2025
Quarterly results filed (8-K) Earnings
—
November 3, 2025
8-K filed: Material agreement, Reg FD disclosure Corporate
—
October 29, 2025
8-K filed: Reg FD disclosure Filing
—
October 29, 2025
8-K filed: Reg FD disclosure Filing
—
September 25, 2025
8-K filed: Leadership change Corporate
—
August 12, 2025
Quarterly results filed (8-K) Earnings
—
June 30, 2025
8-K filed: Leadership change, Other event Corporate
—
May 13, 2025
Quarterly results filed (8-K) Earnings
—
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.